New Members Include Hematologists, NFL Vet,
Operations & Communications Executives; All-Woman Executive
Committee Named
RYE
BROOK, N.Y., July 1, 2024
/PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) named
five new members to its board of directors effective
July 1, 2024, whose diverse
experience and interests will be instrumental in helping the
organization carry out its mission to cure blood cancer and improve
the quality of life of all patients and their families.
LLS proudly welcomes the following new members to its board:
Sharon Castellino, M.D.,
MSc: Dr. Castellino is a Professor of Pediatrics at
Emory University School of Medicine,
where she serves as the Director of the Leukemia and Lymphoma
Program and as the Mark R. Hudgens Chair for Clinical Research in
the Aflac Cancer and Blood Disorders Center of Children's
Healthcare of Atlanta. She is the
founder and co-leader of the leukemia and lymphoma biorepository,
vice chair for the pediatric oncology precision medicine protocol
at CHOA, and a member of the Cancer Prevention and Control Research
Program at Winship Cancer Institute at Emory
University. Nationally, Dr. Castellino serves as the
Scientific Chair for the Children's Oncology Group (COG) Hodgkin
Lymphoma Committee. She has led several seminal clinical trials for
children, adolescents, and young adults with Hodgkin lymphoma and
has been a leader in creating models for collaborative research to
benefit children and adolescents. Dr. Castellino also has expertise
in healthcare delivery research, particularly as it relates to
adolescents, young adults, and under-represented patients.
Mike Farmer: Mr. Farmer
was formerly President of commercial operations at Builders
FirstSource. He led the company's commercial efforts, including
sales and national accounts, marketing, customer segment strategy,
and innovation. In this role, Mr. Farmer was responsible for
leading the implementation of commercial operations best practices
to create sustainable growth and drive innovation through
best-in-class manufacturing capabilities in components, millwork,
and READY-FRAME®, while providing an exceptional
customer experience. Mr. Farmer has been an influential volunteer
for LLS for many years.
Alex Okafor: Mr.
Okafor is a retired nine-year NFL vet and 2020 Super Bowl Champion
with the Kansas City Chiefs. In 2021, he helped launch LLS's
Scholarship for Blood Cancer Survivors, which he continues to
sponsor through his Family Foundation and supports by giving his
time to aspects of the program and other LLS initiatives. Mr.
Okafor is active in his community and currently serves on the
Pflugerville Independent School District Board of Trustees.
Rayne H. Rouce,
M.D.: Dr. Rouce is a board-certified pediatric
hematologist/oncologist at Texas Children's Cancer Center at
Baylor College of Medicine (BCM), where
she is also a physician-scientist. Her clinical and research
interests are harnessing the immune system to target leukemia and
lymphoma. Dr. Rouce has served as the Pediatric Clinical Cell
Therapy Lead, Co-Director of the Immunotherapy Fellowship, and
principal investigator on numerous first-in-human immunotherapy
trials targeting leukemia and lymphoma. Passionate about addressing
health disparities and access to novel treatments and trials, she
leads the Task Force for Promoting Equity in Clinical Trials within
the Dan L Duncan Comprehensive Cancer Center at BCM. Dr. Rouce
supports health equity initiatives within medicine in general and
cancer specifically by serving as the Director of Community
Outreach and Engagement within BCM's Office of Community Engagement
and Health Equity and as the Associate Director of Community
Outreach and Engagement for the Dan L Duncan Comprehensive Cancer
Center. She also leads DEI programs for scientific organizations
such as ASH, ASGCT, and ASTCT. Dr. Rouce actively presents,
advocates, and participates in collaborative groups tackling health
disparities and cancer-related equity issues.
Lilian Stern: Ms.
Stern is Principal of Stern Investor Relations, Inc., a consulting
firm she founded more than 20 years ago, which specializes in
investor relations services for biotechnology companies. The firm
has represented hundreds of public and private companies, more than
30% of which are working on novel oncology therapies. Throughout
Stern IR's history, Ms. Stern has committed to the key value of
contributing to human health by facilitating capital into the
industry.
"Our new members have demonstrated in so many ways their
steadfast commitment to curing blood cancer and improving the
quality of life of all patients and their families," said E.
Anders Kolb, M.D., President and CEO
of LLS. "Having a more inclusive board has been a priority for LLS,
and our new members reflect the diverse needs of the communities we
serve. We are fortunate to benefit from their unique expertise as
we work together to help patients thrive through treatment and
beyond."
LLS's new board members will serve under the newly appointed
Board Chair, Alessandra Tocco. She
heads an all-woman executive committee of officers comprised of
existing members: Freda Wang, Vice
Chair (former Secretary-Treasurer); Marla
Persky, Secretary-Treasurer; and Janice L. Gabrilove, M.D.,
Director-At-Large.
Members continuing to serve on LLS's board include: Rich Bagger, Leroy M.
Ball, Mark J. Barrenechea,
Renzo Canetta, MD, Casey Cunningham, M.D., Jennifer Marley, Ari
Melnick, M.D., Kathleen
Meriwether, Ruben A. Mesa,
M.D., FACP, Lynn F. O'Brien,
Jim Reddoch, Ph.D., Richard M. Rendina, Robert Rosen, Jeff
Sachs, Yvette Tremonti.
Bart Sichel has exited the board and
completed his term on June 30,
2024.
To learn more about LLS's Board of Directors, please visit this
link.
Journalists and reporters seeking additional information, please
contact mediarelations@lls.org.
About The Leukemia & Lymphoma Society (LLS)
The Leukemia & Lymphoma Society® (LLS) is the global
leader in the fight against blood cancer. The LLS mission: Cure
leukemia, lymphoma, Hodgkin's disease, and myeloma, and improve the
quality of life of patients and their families. LLS funds
lifesaving blood cancer research around the world, provides free
information and support services, and is the voice for all blood
cancer patients seeking access to quality, affordable, coordinated
care.
Founded in 1949 and headquartered in Rye Brook, NY, LLS has regions throughout
the United States and Canada. To learn more, visit www.LLS.org.
Patients should contact the Information Resource Center at (800)
955-4572, Monday through Friday, 9 a.m. to 9
p.m. ET.
For additional information, visit lls.org/lls-newsnetwork.
Follow us on Facebook, X, Instagram, LinkedIn and TikTok.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-leukemia--lymphoma-society-welcomes-five-members-to-its-board-of-directors-302186956.html
SOURCE The Leukemia & Lymphoma Society (LLS)